ES2574918T3 - Tratamiento de la fatiga muscular - Google Patents
Tratamiento de la fatiga muscular Download PDFInfo
- Publication number
- ES2574918T3 ES2574918T3 ES04735029.3T ES04735029T ES2574918T3 ES 2574918 T3 ES2574918 T3 ES 2574918T3 ES 04735029 T ES04735029 T ES 04735029T ES 2574918 T3 ES2574918 T3 ES 2574918T3
- Authority
- ES
- Spain
- Prior art keywords
- diabetes
- exercise
- patients
- pcr
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XJINZNWPEQMMBV-UHFFFAOYSA-N CCCCCCNC Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Abstract
Un compuesto para su uso en el tratamiento terapéutico de la disfunción muscular del cuerpo humano o animal mediante la administración de un compuesto a un sujeto que reduce los ácidos grasos libres circulantes en el plasma sanguíneo del sujeto, comprendiendo el compuesto un éster de cuerpos cetónicos.
Description
Datos expresados como media ± ETM. ADP, adenosín difosfato; PCr, fosfocreatina; Pi, fósforo inorgánico; δ(α-β) ATP, diferencias de desplazamiento químico entre los picos de los α-y β-fosfatos del ATP. *, p < 0,05; **, p < 0,01; ***, p < 0,001 vs control.
La Figura 4 muestra ejemplos de espectros músculo esqueléticos antes y al final del protocolo de ejercicio
5 normalizado en un paciente con diabetes tipo 2 y en el tiempo equivalente (5,1 min) de ejercicio en un participante control. En condiciones de reposo, el pH y las concentraciones de PCr (PCr/ATP), ADP libre y fosfato inorgánico músculo esqueléticos eran los mismos en los controles y en los pacientes con diabetes tipo 2 (Tabla 2). Durante el ejercicio, la hidrólisis de la PCr era 2 veces más rápida y la disminución del pH era 3 veces más rápida en los pacientes con diabetes en comparación con los participantes control, pero las velocidades de producción del ADP
10 libre no eran significativamente diferentes (Tabla 2). En todos los participantes, la fatiga aparecía cuando la disminución de la PCr era ~ 50 % (50 ± 4 % en los controles frente a 51 ± 4 % en los diabéticos) y al mismo pH y concentraciones de ADP libre (Tabla 2). Las concentraciones de magnesio libre permanecieron inalteradas durante el ejercicio en todos los participantes (Tabla 2). Tras el ejercicio, la velocidad inicial de recuperación de la PCr era un 25 % menor y los tiempos medios de recuperación de la PCr eran 1,6 veces más largos en los pacientes con
15 diabetes tipo 2 que en los controles, pero los tiempos medios de recuperación del ADP libre eran los mismos (Tabla 2).
Los tiempos de ejercicio se correlacionaban de forma negativa con los niveles de HbA1c (r2 = 0,32; p < 0,01; Figura 5) y los niveles de glucosa en plasma (r2 = 0,23; p < 0,01; correlación no mostrada), pero no había correlaciones con los niveles de ácidos grasos libres o de lactato en plasma. Las velocidades de la hidrólisis de la PCr y la disminución
20 del pH durante el ejercicio no se correlacionaban con ninguna de las concentraciones de los metabolitos en ayunas. Sin embargo, los tiempos medios de recuperación de la PCr se correlacionaban de forma positiva con los niveles de HbA1c (r2 = 0,40; p < 0,001; correlación no mostrada), y las concentraciones de glucosa en plasma (r2 = 0,16; p < 0,05; correlación no mostrada) para todos los participantes, si bien no había correlaciones con las concentraciones de ácidos grasos libres o lactato en plasma.
25 Oxigenación músculo esquelética
En reposo, la saturación de oxígeno en el músculo gastrocnemio era estable y era la misma para ambos grupos, del 68 % en los controles y del 71 % en los diabéticos, y todos los participantes dejaron de hacer ejercicio tras una disminución del 11 % de la oxigenación tisular medida usando NIRS (Tabla 2). El primer paciente diabético dejó de hacer ejercicio al cabo de 3 min (Figura 4), por tanto, durante los 3 primeros minutos de ejercicio, la velocidad de 30 desoxigenación era 3,1 veces más rápida en los pacientes con diabetes tipo 2 que en los controles (Tabla 2), y se correlacionaba con el tiempo de ejercicio (r2 = 0,29, p < 0,01, Figura 5). Análogamente, los tiempos de reoxigenación durante la recuperación tras el ejercicio eran 2,5 veces más largos en los pacientes con diabetes que en los controles (Tabla 2), que se correlacionaban con los niveles de HbA1c (r2 = 0,35; p < 0,01; Figura 5) y con los tiempos medios de recuperación de la PCr (r2 = 0,25; p < 0,01; Figura 5) en todos los participantes, pero no con los niveles
35 de ácidos grasos libres o lactato en plasma.
Los resultados anteriores demuestran que el aumento de los ácidos grasos libres, asociado a la diabetes tipo 2, puede contribuir a la disfunción muscular, particularmente a la disfunción muscular cardíaca. Estos descubrimientos también son relevantes para otros trastornos/afecciones asociados a niveles elevados de ácidos grasos libres, y por ello la reducción de los ácidos grasos libres puede ser un objetivo general en la reducción de la probabilidad de la
40 disfunción muscular, por ejemplo, de la insuficiencia cardíaca.
1. Schernthaner G. "Cardiovascular mortality and morbidity in type-2 diabetes mellitus". Diabetes Res Clin Pract. 1996; 31:S3-S13.
2. Taegtmeyer H, McNulty P, Young ME. "Adaptation and maladaptation of the heart in diabetes: Part I. General 45 concepts". Circulation. 2002; 105:1727-1733.
- 3.
- Iribarren C, Karter AJ, Go AS, y col. "Glycemic control and heart failure among adult patients with diabetes". Circulation. 2001; 103:2668-2673.
- 4.
- Rodrigues B, Cam MC, McNeill JH. "Metabolic disturbances in diabetic cardiomyopathy". Mol CellBiochem. 1998;180:53-57.
50 5. Chatham JC, SeymourA-ML. "Cardiac carbohydrate metabolism in Zucker diabetic fatty rats". Cardiovasc Res. 2002; 55:104-112.
6. Sidell RJ, Cole MA, Draper NJ, y col. "Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart". Diabetes. 2002; 51:1110-1117.
7. Stanley WC, Lopaschuk GD, McCormack JG. "Regulation of energy substrate metabolism in the diabetic 55 heart". Cardiovasc Res. 1997;34:25-33.
- 8.
- Tune JD, Yeh C, Setty S, y col. "Coronary blood flow control is impaired at rest and during exercise in conscious diabetic dogs". Basic Res Cardiol. 2002; 97:248-257.
- 9.
- Meyer C, Schwaiger M. "Myocardial blood flow and glucose metabolism in diabetes mellitus". Am J Cardiol.
1997; 80:94A-101A. 60 10. lozzo P, Chareonthaitawee P, Rimoldi O, y col. "Mismatch between insulin-mediated glucose uptake and
9
blood flow in the heart of patients with Type II diabetes". Diabetologia 2002; 45:1404-1409.
11. Baron AD, Laakso M, Brechtel G, y col. "Mechanism of insulin resistance in insulin-dependent diabetes mellitus: A major role for reduced skeletal muscle blood flow". J Clin Endocrinol Metab. 1991; 73:637-643.
12. Demir I, Ermis C, Altunbas H, y col. "Serum HbA1c levels and exercise capacity in diabetic patients". Jpn 5 Heart J. 2001; 42:607-616.
- 13.
- Estacio RO, Regensteiner JG, Wolfel EE, y col. "The association between diabetic complications and exercise capacity in NIDDM patients". Diabetes Care. 1998; 21:291-295.
- 14.
- Crilley JG, Boehm EA, Rajagopalan B, y col. "Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy". J Am Coll Cardiol. 2000; 36:1953-1958.
10 15. Lodi R, Kemp GJ, Muntoni F, y col. "Reduced cytosolic acidification during exercise suggests defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. An in vivo 31P magnetic resonance spectroscopy study". Brain. 1999; 122:121-130.
16. Veech RL, Lawson JWR, Cornell NW, y col. "Cytosolic phosphorylation potential". J Biol Chem. 1979;
254:6538-6547. 15 17. Madsen PL, Secher NH. "Near-infrared oximetry of the brain". Prog Neurobiol. 1999; 58:541-560.
- 18.
- Neubauer S, Horn M, Cramer M, y col. "Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy". Circulation. 1997; 96:2190-2196.
- 19.
- Boehm EA, Jones BE, Radda GK, y col. "Increased uncoupling proteins and decreased efficiency in the palmitateperfused hyperthyroid rat heart". Am J Physiol. 2001; 280: H977-H983.
20 20. Chatham JC, Gao ZP, Bonen A, y col. "Preferential inhibition of lactate oxidation relative to glucose oxidation in the rat heart following diabetes". Cardiovasc Res. 1999; 43:96-106.
21. Libby P, Plutzky J. "Diabetic macrovascular disease. The glucose paradox?" Circulation. 2002; 106:27602763.
22. Mahler RJ, Adler ML. "Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment". J Clin 25 Endocrinol Metab. 1999; 84:1165-1171.
23. Komiyama T, Shigematsu H, Yasuhara H, y col. "Near-infrared spectroscopy grades the severity of intermittent claudication in diabetes more accurately than ankle pressure measurement". Br J Surg. 2000; 87:459
466.
10
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0312603 | 2003-06-02 | ||
GB0312603A GB0312603D0 (en) | 2003-06-02 | 2003-06-02 | Method |
GB0313760 | 2003-06-13 | ||
GB0313760A GB0313760D0 (en) | 2003-06-13 | 2003-06-13 | Method |
PCT/GB2004/002286 WO2004105742A1 (en) | 2003-06-02 | 2004-05-27 | Treatment of muscle fatigue |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2574918T3 true ES2574918T3 (es) | 2016-06-23 |
Family
ID=33492255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04735029.3T Active ES2574918T3 (es) | 2003-06-02 | 2004-05-27 | Tratamiento de la fatiga muscular |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060078596A1 (es) |
EP (1) | EP1641444B1 (es) |
DK (1) | DK1641444T3 (es) |
ES (1) | ES2574918T3 (es) |
WO (1) | WO2004105742A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004108740A2 (en) | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
ES2730879T3 (es) | 2008-01-04 | 2019-11-13 | Univ Oxford Innovation Ltd | Cuerpos de cetona y ésteres de cuerpos de cetona como agentes reductores de lípidos de la sangre |
PL2328858T3 (pl) | 2008-08-21 | 2018-06-29 | Oxford University Innovation Limited | Napój zawierający ester hydroksymaślanu i jego zastosowanie medyczne |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
US20130127466A1 (en) * | 2011-05-27 | 2013-05-23 | 02 Insights, Inc. | Systems and methods for assessment of oxygenation |
GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
US9579302B2 (en) | 2012-11-05 | 2017-02-28 | Tdeltas | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
CA2905225C (en) | 2013-03-14 | 2021-05-04 | Isis Innovation Limited | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
US9163202B2 (en) | 2013-08-02 | 2015-10-20 | Eastman Chemical Company | Aqueous cleaning compositions including an alkyl 3-hydroxybutyrate |
US9388114B2 (en) | 2013-08-02 | 2016-07-12 | Eastman Chemical Company | Compositions including an alkyl 3-hydroxybutyrate |
US9249378B2 (en) | 2013-08-02 | 2016-02-02 | Eastman Chemical Company | Aqueous cleaning compositions having enhanced properties |
US9255059B2 (en) | 2013-08-02 | 2016-02-09 | Eastman Chemical Company | Method for producing an alkyl 3-hydroxybutyrate |
GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
US20170049856A1 (en) * | 2014-04-28 | 2017-02-23 | Juventas Therapeutics, Inc. | Sdf-1 delivery for treating advanced ischemic cardiomyopathy |
US20220257546A1 (en) | 2019-05-10 | 2022-08-18 | Ketoswiss Ag | Ketone bodies enclosed in microbeads |
CN116528848A (zh) | 2020-11-05 | 2023-08-01 | 奥胡斯大学 | 乳酸/酮体酯 |
WO2023213874A1 (en) | 2022-05-04 | 2023-11-09 | Aarhus Universitet | Combined lactate and ketone body esters for medical and nutritional use |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2873497B2 (ja) * | 1990-09-03 | 1999-03-24 | 理化学研究所 | 脂質代謝調節剤 |
EP0537113A1 (en) * | 1991-10-10 | 1993-04-14 | SANDOZ NUTRITION Ltd. | Energy supplementary food |
US5468507A (en) * | 1993-07-13 | 1995-11-21 | Czap; Al F. | Composition containing a desired flavoring agent and medium chain triglycerides |
DE4427492A1 (de) * | 1994-08-03 | 1996-02-08 | Boehringer Mannheim Gmbh | Verfahren zur Analyse einer medizinischen Probe unter Vermeidung von Störbeiträgen aufgrund von Hämolyse |
JPH10175855A (ja) * | 1996-10-16 | 1998-06-30 | Taisho Pharmaceut Co Ltd | 肉体疲労改善剤 |
US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
US6232346B1 (en) * | 1997-03-27 | 2001-05-15 | Michael J. Sole | Composition for improvement of cellular nutrition and mitochondrial energetics |
US6727258B2 (en) * | 1997-10-29 | 2004-04-27 | King Pharmaceutical Research & Development, Inc. | Allosteric adenosine receptor modulators |
GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
DE60135439D1 (de) * | 2000-01-14 | 2008-10-02 | Serono Genetics Inst Sa | Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes |
US6970737B1 (en) * | 2000-09-13 | 2005-11-29 | Ge Medical Systems Information Technologies, Inc. | Portable ECG device with wireless communication interface to remotely monitor patients and method of use |
AUPR177300A0 (en) * | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
DE20205184U1 (de) * | 2002-03-27 | 2002-12-19 | Bartz Volker | Blutfettsenker zur oralen Einnahme |
US8996090B2 (en) * | 2002-06-03 | 2015-03-31 | Exostat Medical, Inc. | Noninvasive detection of a physiologic parameter within a body tissue of a patient |
CN1483355A (zh) * | 2002-09-16 | 2004-03-24 | 岚 高 | 抗疲劳饮料配方 |
US20050181275A1 (en) * | 2004-02-18 | 2005-08-18 | Jang Bor Z. | Open electrochemical cell, battery and functional device |
-
2004
- 2004-05-27 WO PCT/GB2004/002286 patent/WO2004105742A1/en active Application Filing
- 2004-05-27 ES ES04735029.3T patent/ES2574918T3/es active Active
- 2004-05-27 EP EP04735029.3A patent/EP1641444B1/en active Active
- 2004-05-27 DK DK04735029.3T patent/DK1641444T3/en active
-
2005
- 2005-11-28 US US11/287,803 patent/US20060078596A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1641444B1 (en) | 2016-03-23 |
US20060078596A1 (en) | 2006-04-13 |
WO2004105742A1 (en) | 2004-12-09 |
DK1641444T3 (en) | 2016-06-27 |
EP1641444A1 (en) | 2006-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2574918T3 (es) | Tratamiento de la fatiga muscular | |
Persky et al. | Clinical pharmacology of the dietary supplement creatine monohydrate | |
CA2140768C (en) | A method of increasing creatine supply depot | |
Peng et al. | High extracellular potassium concentrations stimulate oxidative metabolism in a glutamatergic neuronal culture and glycolysis in cultured astrocytes but have no stimulatory effect in a GABAergic neuronal culture | |
Stacpoole | Lactic acidosis | |
Raab | Key position of catecholamines in functional and degenerative cardiovascular pathology∗ | |
Zhang et al. | Bioenergetic abnormalities associated with severe left ventricular hypertrophy. | |
US4968719A (en) | Method for treating vascular disease | |
Taegtmeyer et al. | Substrate metabolism as a determinant for postischemic functional recovery of the heart | |
Van Hall | Lactate kinetics in human tissues at rest and during exercise | |
Block et al. | Valine metabolism in vivo: effects of high dietary levels of leucine and isoleucine | |
Luzi et al. | Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM | |
Suzuki et al. | Effects of L-carnitine on arrhythmias during hemodialysis | |
JP2016153421A (ja) | エネルギーをインビボで増加させるための組成物 | |
Essén et al. | Regulation of glycolysis in intermittent exercise in man. | |
Davis III et al. | Mechanical ventilation reduces rat diaphragm blood flow and impairs oxygen delivery and uptake | |
Rao et al. | Neurochemical changes in the developing rat hippocampus during prolonged hypoglycemia | |
Ruddy et al. | The relationship of cardiac diastolic dysfunction to concurrent hormonal and metabolic status in type I diabetes mellitus | |
SK11252003A3 (sk) | Kompozície biochemických zlúčenín zúčastňujúcich sa bioenergetického metabolizmu buniek a ich použitie | |
Takeuchi et al. | Administration of fructose 1, 6-diphosphate during early reperfusion significantly improves recovery of contractile function in the postischemic heart | |
Dodd et al. | The role of ribose in human skeletal muscle metabolism | |
Panov | Synergistic oxidation of fatty acids, glucose and amino acids metabolites by isolated rat heart mitochondria | |
US20030212006A1 (en) | Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals | |
DiNuzzo et al. | State-dependent changes in brain glycogen metabolism | |
Mori et al. | Endothelium-dependent relaxation of rat thoracic aorta by amrinone-induced nitric oxide release |